Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer
Open Access
- 27 September 2022
- journal article
- research article
- Published by Elsevier in Cell Reports Medicine
- Vol. 3 (10) , 100781
Abstract
No abstract availableKeywords
Funding Information
- Cilag (C11496/A30025)
- Horizon 2020 Framework Programme (892360)
- Wellcome Trust (FC0010218)
- National Institute for Health and Care Research
- Entertainment Industry Foundation
- American Association for Cancer Research
- University College London Hospitals Biomedical Research Centre
- Melanoma Research Alliance
- Royal Marsden Cancer Charity
- Institute of Cancer Research (A109)
- Royal Society (RP/EA/180007)
- Cancer Research UK (C50947/A18176)
- European Society for Medical Oncology
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- Manchester Biomedical Research Centre
- Royal Marsden NHS Foundation Trust (RMCC32)
- Horizon 2020
- Rosetrees Trust (M926)
- Rosetrees Trust (A2204)
- European Research Council (RP150154)
- European Research Council (835297)
- Novo Nordisk Fonden (ID16584)
- Breast Cancer Research Foundation (BCRF 20-157)
- Francis Crick Institute (FC001030)
- Francis Crick Institute (FC001169)
- Francis Crick Institute (FC001002)
- Francis Crick Institute (FC001099)
- Francis Crick Institute (FC001218)
- Francis Crick Institute (FC011104)
- Francis Crick Institute (FC001988)
- Francis Crick Institute (FC001078)
- UK Research and Innovation (203135)
- UK Research and Innovation (222754)
- UK Research and Innovation (MR/W005611/1)
- National Institutes of Health
- Medical Research Council
This publication has 29 references indexed in Scilit:
- Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studyNature Cancer, 2021
- Covid-19 Breakthrough Infections in Vaccinated Health Care WorkersNew England Journal of Medicine, 2021
- Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strainseLife, 2021
- AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOCThe Lancet, 2021
- Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccinationThe Lancet, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Cancer, COVID-19, and Antiviral Immunity: The CAPTURE StudyCell, 2020
- A minimal common outcome measure set for COVID-19 clinical researchThe Lancet Infectious Diseases, 2020
- A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumabSeminars in Oncology, 2017
- Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome CoronavirusJournal of Virology, 2005